Opko Health (NASDAQ: OPK) is one of 113 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Opko Health to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, earnings, valuation, dividends and risk.

Earnings and Valuation

This table compares Opko Health and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Opko Health $1.18 billion -$17.02 million -40.47
Opko Health Competitors $7.79 billion $2.46 billion -0.08

Opko Health’s competitors have higher revenue and earnings than Opko Health. Opko Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Opko Health and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opko Health -6.52% -3.67% -2.78%
Opko Health Competitors -3,075.31% -52.43% -9.03%

Analyst Recommendations

This is a summary of recent ratings and target prices for Opko Health and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opko Health 0 3 6 0 2.67
Opko Health Competitors 797 3421 5869 137 2.52

Opko Health presently has a consensus target price of $14.81, suggesting a potential upside of 115.30%. As a group, “Pharmaceuticals” companies have a potential upside of 22.28%. Given Opko Health’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Opko Health is more favorable than its competitors.

Risk & Volatility

Opko Health has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Opko Health’s competitors have a beta of 0.87, meaning that their average share price is 13% less volatile than the S&P 500.

Institutional and Insider Ownership

22.5% of Opko Health shares are owned by institutional investors. Comparatively, 43.1% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 40.2% of Opko Health shares are owned by insiders. Comparatively, 12.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


Opko Health beats its competitors on 8 of the 12 factors compared.

About Opko Health

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.